Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier

Navarro, Alba; Clot Razquin, Guillem; Martínez Trillos, Alejandra; Pinyol, Magda; Jares Gerboles, Pedro; González Farré, Blanca; Martínez, Daniel; Trim, Nicola; Fernàndez Pascual, Verònica; Villamor i Casas, Neus; Colomer Pujol, Dolors; Costa, Dolors; Salaverria Frigola, Itziar; Martín García, David; Erber, Wendy; López González, Cristina; Jayne, Sandrine; Siebert, Reiner; Dyer, Martin J. S.; Wiestner, Adrian; Wilson, Wyndham H.; Aymerich Gregorio, Marta; López Guillermo, Armando; Sànchez, Àlex (Sànchez Pla); Campo Güerri, Elias; Matutes, Estella; Beà Bobet, Sílvia M.; Navarro, Alba; Clot Razquin, Guillem; Martínez Trillos, Alejandra; Pinyol, Magda; Jares Gerboles, Pedro; González Farré, Blanca; Martínez, Daniel; Trim, Nicola; Fernàndez Pascual, Verònica; Villamor i Casas, Neus; Colomer Pujol, Dolors; Costa, Dolors; Salaverria Frigola, Itziar; Martín García, David; Erber, Wendy; López González, Cristina; Jayne, Sandrine; Siebert, Reiner; Dyer, Martin J. S.; Wiestner, Adrian; Wilson, Wyndham H.; Aymerich Gregorio, Marta; López Guillermo, Armando; Sànchez, Àlex (Sànchez Pla); Campo Güerri, Elias; Matutes, Estella; Beà Bobet, Sílvia M.

Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier

Fecha de publicación

2018-06-11T11:21:10Z

2017-09

2018-06-11T11:21:10Z

Resumen

B-cell chronic lymphoproliferative disorders (B-CLPD) encompass a group of hematologic tumors that often present with leukemic involvement.1 Their heterogeneity and the lack of relatively specific diagnostic markers for most of these diseases make their diagnosis challenging, especially in cases that only have blood involvement or when histology is not available. With the currently used immunophenotypic and molecular markers, around 10% of B-CLPD cases remain unclassifiable and are categorized as B-CLPD, not otherwise specified (B-CLPD, NOS).